According to the findings, the antiviral treatment demonstrated to significantly reduce the transmission of influenza viruses ...

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...

Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...

It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company said Wednesday. Treatment with a single dose of Xofluza within 48 ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...